Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

10-1-2015

In vitro testing for diagnosis of idiosyncratic adverse drug
reactions: Implications for pathophysiology
Abdelbaset A. Elzagallaai
Schulich School of Medicine & Dentistry

Michael J. Rieder
Schulich School of Medicine & Dentistry, mrieder@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Elzagallaai, Abdelbaset A. and Rieder, Michael J., "In vitro testing for diagnosis of idiosyncratic adverse
drug reactions: Implications for pathophysiology" (2015). Paediatrics Publications. 2066.
https://ir.lib.uwo.ca/paedpub/2066

DOI:10.1111/bcp.12505

British Journal of Clinical
Pharmacology

In vitro testing for diagnosis
of idiosyncratic adverse drug
reactions: Implications for
pathophysiology
Abdelbaset A. Elzagallaai1 & Michael J. Rieder1,2,3,4

Correspondence
Dr Michael J. Rieder MD, PhD, FRCPC,
Division of Clinical Pharmacology,
Children’s Hospital, 800 Commissioner’s
Road East London, Ontario, Canada, N6C
2V5.
Tel.: +1 (519) 685 8293
Fax: +1 (519) 685 8156
E-mail: mrieder@uwo.ca
-----------------------------------------------------------------------

Keywords
adverse drug events, adverse drug
reactions, drug allergy, idiosyncratic drug
reactions, in vitro diagnosis
-----------------------------------------------------------------------

1

Department of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario,
London, Ontario, 2Department of Medicine, Schulich School of Medicine and Dentistry, University of
Western Ontario, London, Ontario, 3Department of Physiology and Pharmacology, Schulich School of
Medicine and Dentistry, University of Western Ontario, London, Ontario and 4CIHR-GSK Chair in
Pediatric Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western
Ontario, London, Ontario, Canada

Received
31 March 2014

Accepted
31 August 2014

Accepted Article
Published Online
9 September 2014

Idiosyncratic drug reactions (IDRs) represent a major health problem, as they are unpredictable, often severe and can be life
threatening. The low incidence of IDRs makes their detection during drug development stages very difficult causing many
post-marketing drug withdrawals and black box warnings. The fact that IDRs are always not predictable based on the drug’s known
pharmacology and have no clear dose–effect relationship with the culprit drug renders diagnosis of IDRs very challenging, if not
impossible, without the aid of a reliable diagnostic test. The drug provocation test (DPT) is considered the gold standard for diagnosis
of IDRs but it is not always safe to perform on patients. In vitro tests have the advantage of bearing no potential harm to patients.
However, available in vitro tests are not commonly used clinically because of lack of validation and their complex and expensive
procedures. This review discusses the current role of in vitro diagnostic testing for diagnosis of IDRs and gives a brief account of their
technical and mechanistic aspects. Advantages, disadvantages and major challenges that prevent these tests from becoming
mainstream diagnostic tools are also discussed here.

Introduction
Idiosyncratic drug reactions (IDRs), are important health
problems that can cause extra patient suffering or death
and high healthcare cost. Accurate diagnosis is key to
effective management and prevention. Clinical diagnosis
of IDRs can be difficult and often is inaccurate, if based
only on medical history and physical examination. While
drug provocation testing (DPT) (drug challenge or systemic re-exposure) is considered the gold standard for
diagnosis of IDRs, it can be ethically problematic to
perform due to possible severe consequences and it is
contraindicated in patients with suspected severe reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal neclolysis (TEN) and DRESS (Drug Rash with
Eosinophilia and Systemic Symptoms) syndrome [1].
Other in vivo tests such as the patch test or transdermal
© 2014 The British Pharmacological Society

applications may cause reaction flare-ups or even systemic reactions [2]. Currently, known in vitro tests are not
in wide clinical use largely due to their complicated and
expensive procedures as well as their undetermined predictive values [3, 4]. This review evaluates the role of in
vitro testing for the diagnosis of IDRs and discusses some
technical and mechanistic aspects, and challenges that
prevent these tests from becoming a mainstream clinical
approach in management of IDRs.
According to the classification proposed by Rawlins &
Thompson adverse drug reactions (ADRs) are either type A
reactions, which are predictable, dose-dependent and
related to the pharmacological action of the drug or type B
reactions, which are unpredictable, have delayed onset,
typically unrelated to the drug pharmacology (or at least
the known pharmacology) and do not have clear dosedependency [5]. Type A ADRs are the most common and
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Adverse drug reactions
Rawlins & Thompson classification

Type A (~75%)
‘Augmented’

Type B (~25%)
‘Bizarre’
Idiosyncratic drug
reactions (IDRs)

HSR to vaccines

Excessive therapeutic
effects

Side effects

Due to drug overdose

Organ-specific effects

Hypersensitivity reactions
‘Drug allergy’

Due to drug–drug
interaction

Drug intolerance

Gell & Coombs classification

Non-immune IDRs
(Pseudoallergy)

Due to patient
condition
Type I
lgE-mediated

Type II
Type III
Type IV
lgG-mediated Complement-mediated T-cell-mediated

Genetics Disease
Gender

Affect
drug PK

Age

Affect
drug PD

Type IVa
Type IVb
Th1 cells, IFNg, Th2 cells, IL-4
TNFa
IL-5/IL-13

Type IVc
Type IVd
cytotoxic T-cells,
T-cells, CXCL-8,
Perforin Granzyme B, FasL
GM-CSF

Figure 1
Classification of adverse drug reactions (see text for details)

account for 75%–80%, while type B represent 20%–25% of
all ADRs (Figure 1).

Type B ADRs (IDRs)
Type B ADRs are also called IDRs. The term means that the
reaction is specific to the individual and it is impossible to
predict without an identified genetic marker. IDRs include
ADRs such as ‘drug hypersensitivity’, which can be either
immune-mediated and called allergic hypersensitivity or, if
the immunologic mechanism is excluded, is called nonallergic hypersensitivity (pseudoallergy) [6, 7]. The term
‘hypersensitivity’ does not necessarily imply any immune
system involvement and has been defined as ‘objectively
reproducible symptoms or signs, initiated by exposure to a
defined stimulus at dose tolerated by normal subjects’ [8,
9]. Drug hypersensitivity reactions have been estimated to
represent approximately one-sixth of all ADRs. However,
their precise incidence is not known due to underreporting [10].
Immune-mediated IDRs are classified according to the
Combs & Gells classification into four types (I–IV); Type I is
mediated by immunoglobulin E (IgE), type II is mediated
by IgG and IgM, type III is mediated by formation of an
immune complement complex and type IV is T-cell mediated (Table 1) [11]. Despite being a useful classification,
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many recently understood immune-mediated reactions
do not fit into the four Combs & Gells classes. A revised and
more detailed system has now been introduced [12]. It is
also of clinical relevance to classify IDRs according to the
time required for the symptoms to appear into immediate
reactions (≤1 h, e.g. anaphylaxis), intermediate (5–14 days)
and delayed (2–7 weeks, Table 1) [13].
Related to their low incidence, IDRs are difficult to
detect during drug development clinical trials and there
are only few validated animal models to perform any
mechanistic studies [14]. Also their unpredictability
renders prospective studies in humans very difficult, if not
impossible. Therefore, our understanding of the underlying pathophysiology of IDRs is still lacking and their classification and nomenclature remains debated. However,
IDRs appear to be immune-mediated in many cases [10,
15–19]. Evidence that supports this hypothesis includes
the delayed nature of these types of reactions and that the
time between exposure and appearance of the symptoms
shortens, if the patient is pre-exposed to the agent,
although some exceptions do occur. Drug-specific T-cells
have also been detected in the peripheral blood of the
affected individuals [20].
Although the skin, liver and blood cells are the most
commonly affected, IDRs can affect any organ and
patients can present with fever, skin rash (including
maculopapular, morbilliform, urticarial, fixed drug

In vitro testing for idiosyncratic adverse drug reactions

Table 1
Classification of immune-mediated IDRs

Type

Mediator

Pathogenesis

Clinical picture

Chronology

I

IgE

Degranulation of mast cells and basophils

II

IgG/M

FcR dependent cell lysis

Urticaria, anaphylaxis, allergic rhinitis,
bronchospasm, angio-oedema
Blood cell dyscrasia

Immediate
(≤1 h)
Intermediate
(5–14 days)

III

IgG/M

FcR-dependent immune complexes deposition

IVa

TH1 (IFNγ, TNFα)

Monocyte/macrophage mediated inflammatory response

Serum sickness, vasculitis,
arthus reaction
Eczema

Intermediate
(7–8 days)
Delayed
(1–3 weeks)

IVb

TH2-IL4, IL5, IL13)

Eosinophils mediated inflammatory response

IVc

Cytotoxic T cells (Perforine, Granzym B, FasL)

Cytotoxicity/apoptosis

Maculopapular exanthema,
bullous exanthema
Maculopapular exanthema,
bullous/pustular exanthema

Delayed
(2–7 weeks)
Delayed
(1–3 weeks)

IVd

T cells (IL8, CXCL8, GM-CSF)

Neutrophils mediated inflammatory response

AGEP, Behςet’s disease

Intermediate
(≤2 days)

eruption or severe bullous reactions such as SJS and TEN),
blood dyscrasias (eosinophilia and thrombocytopenia),
hepatitis, nephritis, myocarditis, thyroiditis, interstitial
pneumonitis and encephalitis. The case can present with
any combination of these symptoms. Idiosyncratic druginduced liver injury (IDILI) is a common ADR to drugs
including antibiotics (amoxicillin/clavulan), non-steroidal
anti-inflammatory drugs (NSAIDs), isoniazid, sulfamethoxazole, nitrofurantoin, phenytoin and anti-fungals [21].
It can be hepatocellular, cholestatic or mixed based on the
biochemical pattern of liver function tests. The true incidence of IDILI is difficult to determine due to lack of data
on the drug usage although some studies have estimated
the annual incidence to be between 15–20 cases per
100 000 inhabitants [22, 23]. IDILI can also develop as part
of DRESS. Evidence exists that implies the involvement of
the immune system in the underlying pathophysiology of
IDILI [24].
The molecular mechanism(s) underlying IDRs is not
fully understood although thought to be immunemediated in cases where the immune-mechanism is demonstrated [10, 25, 26]. It is noteworthy here that some
IDRs exist, which are not mediated through the immune
system (e.g. IDRs to NSAIDs). For immune-mediated IDRs,
generation of reactive nucleophiles that are able to modify
covalently endogenous macromolecules (proteins and
DNA) through metabolism is thought to be an important
step in the cascade of events leading to activation of the
immune system and eliciting the reaction [14, 15, 21, 27].
Several hypotheses have been proposed in an attempt to
explain the mechanistic pathophysiology of IDRs [10, 12,
16, 28–31]. Briefly, accumulated reactive nucleophiles
metabolites (the reactive metabolite hypothesis) can
modify endogenous macromolecules rendering them
antigenic (the hapten hypothesis) and also provide,
through causing damage and stress to neighbouring cells,

‘danger signals’ (the danger hypothesis) resulting in maturation of antigen presenting cells (APCs) and T-cells
involved in the immune response. The parent molecule
and, possibly its reactive metabolite can also interact
with the immune receptors directly and non-conelantly
producing direct stimulation as per the ‘p-i hypothesis’
(pharmacological interaction of drugs with the immune
system) [32].
Discussing the molecular pathophysiology of IDRs in
detail is beyond the scope of this review. For further
details we suggest these recent references [12, 17, 18, 25,
30, 33].

Diagnosis of IDRs
Clinicians should bear in mind the possibility of an ADR
once a patient has presented with an unexpected event.
Patient medical history including a history of drug allergy
may give an important clue to the case. Drugs that are
known to cause IDRs should be treated as a red flag even
if other differential diagnoses exist. Patients on polypharmacy represent a major challenge as identifying the
culprit drug among multiple drugs has often proved to be
difficult and discontinuing important drugs is not always
a feasible option. Diagnosis of IDRs is two-fold: i) identifying the reaction as an IDR and ii) determining the culprit
drug. Different strategies exist to achieve both goals. Currently the diagnosis of drug hypersensitivity is made on
clinical grounds. The process of clinical diagnosis begins
with the development of a differential diagnosis factoring
in all possible aetiologies. The differential diagnosis is narrowed as the findings of the history and physical examination are factored in, which can include certain entities
and exclude others. Classical laboratory tests can also be
included in this consideration, although they frequently
Br J Clin Pharmacol
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are not very helpful in the case of the evaluation of possible drug hypersensitivity. When all of the elements of
history and physical examination have been considered,
the clinician must then decide on the basis of probabilities, which is the most likely diagnosis. The nature of this
process highlights the importance of accurate reporting
of findings. As an example, SJS is characterized by
erythema multiforme associated with mucositis. The
mucositis is typically inflammatory and often very painful.
In this context, drugs are often the causative agent. In the
case of a patient with erythema multiforme and swollen
lips with no evidence of mucositis, the diagnosis is more
likely erythema multiforme major and not SJS, in which
case the aetiology is much more likely to be infectious.
The difficulty in making an accurate clinical diagnosis
points to the need for a more objective standard for
diagnosis.

In vitro approaches to IDRs
A reliable and safe in vitro diagnostic test for IDRs would
have a profound effect on the clinical management of
IDRs. Although several in vitro tests for IDRs have been
recently developed and optimized, their real predictive
values are yet to be determined accurately [3, 4, 34–36].
Selection of an in vitro diagnostic test for IDRs depends on
the type of reactions and the underlying pathophysiology
predicted from the clinical picture and the natural history
of the reaction. Immediate, IgE-mediated and delayed
T-cell mediated reactions require different sets of in vitro
tests for their diagnosis.

In vitro tests for immediate IgE-mediated IDRs
Detection of drug-specific IgE antibody Measuring drugspecific IgE is the most commonly used diagnostic test for
allergic diseases [37]. The test is based on quantification
of specific IgE antibodies using different laboratory
techniques. The radioallergosorbent test (RAST), cellular
fluorescent assay-IgE (CAP-IgE) and enzyme-linked immunosorbent assay (ELISA) are commonly used technologies.
Although the radioactive technique is no longer used,
‘RAST’ has become a generic name for the technique.
Technical and mechanistic aspects In the test procedure,
suspected antigen (drug) bound to the insoluble phase is
incubated with a serum sample from the patient, washed,
and then bound IgE is quantified using labelled anti IgE
antibody. Direct detection of a drug-specific IgE in patient
blood is a strong indicator of an immune reaction but this
is not necessarily true in all cases. An individual may have
circulating IgE that recognizes a drug molecule without
having an immune reaction towards that drug. Nevertheless, the test is known to have high positive predictive
value (PPV) when combined with good clinical and
medical history. Its negative predictive value (NPV) is
892
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inherently low, which is probably due to the low sensitivity
of the currently used techniques to detect low titres
of circulating immunoglobulins [38, 39]. Thus, positive
results strongly indicate immune mediation of the reaction
but negative results do not exclude the reaction. In such
cases and if the clinical history is highly suggestive of an
allergic reaction, either skin tests or DPT are required to
determine safety of future therapy. The low clinical sensitivity of IgE measurement renders the test of limited usefulness as a diagnostic tool. One commercially available
test (CAP-FEIA, Phadia®) has a sensitivity and specificity of
0% to 25% and 83.3% to 100%, respectively, in diagnosis of
immediate reactions to β-lactam antibiotics [40]. Measurement of drug specific IgE antibodies is widely used for
diagnosis of immediate reactions to β-lactam antibiotics,
muscle relaxants and some NSAIDs [41, 42]. Levels of specific IgE antibodies tend to decrease over time in patients
with immediate allergic reactions, which leads to a
decrease in the test sensitivity over time. Therefore, the
test must be done as soon as possible after the reaction
[43]. Another pitfall of in vitro measurement of drugspecific IgE is the high false positive results in patients with
high total IgE levels and high false negative in patients
with high IgG levels [37].
Basophil activation test (BAT) The BAT is a useful diagnostic tool for immediate IgE-mediated reactions to both
foods and drugs. Its major limitation is the low count of
basophil in peripheral blood, but recent flow cytometric
techniques have allowed the use of whole blood samples
and more accurate determination of the levels of different
markers. Its other pitfall is the low sensitivity and this
problem is tackled by using different cut off values when
evaluating activation markers by flow cytometry [44].
However, the timing of the test with regard to the initial
reaction is very critical as the test tends to lose its sensitivity with time [45]. On the other hand, time during which
basophils maintain their activity after blood sampling
seems to be short and it has been recommended that
samples are processed within 3 h of sampling [46], which
limits the availability of the test. The test is quite reproducible but only when used with a limited number of standardized drugs [47].
Basophils are effector cells in immediate-type hypersensitivity reactions and they respond to antigen stimulation in vitro by degranulation (e.g. release of histamine and
leukotrienes) and expression of certain surface markers
including CD45, CD11b, CD11c, CD62L, CD203c and CD63.
Originally, the BAT was performed by measuring the
release of histamine. Alternatively, flow cytometry based
techniques are now used to measure specific surface
markers that are up-regulated during basophil activation.
The most commonly used are the antigens CD63, also
known as lysosomal-associated membrane glycoprotein-3
(LAMP-3) and CD203c, a glycosylated type II transmembrane molecule [48].

In vitro testing for idiosyncratic adverse drug reactions

The BAT has been validated for type I reactions to
muscle relaxants [49], β-lactam antibiotics [50], pyrazolones and NSAIDs [51, 52]. Sensitivity of the test for
reactions to β-lactam antibiotics, quinolones and
rocuonium was reported as 33–67%, 71.1% and 80%,
respectively [53–55].
The lymphocyte transformation test (LTT) The LTT is discussed in details below as part of the in vitro tests for
delayed type IDRs. Nevertheless, positive LTT results have
been obtained on samples from patients suspected with
immediate type I (IgE-mediated) reactions to β-lactam
antibiotics [56, 57]. This observation is attributed to the
involvement of activated T-cells in the process of producing drug-specific IgE in immediate type allergic reactions.
However, the meaning of detecting drug-specific T-cells in
IgE-mediated reactions remains unkown [58].

In vitro tests for delayed
(T-cell-mediated) IDRs
Delayed, T-cell-mediated, IDRs are believed to be a result
of a complex interplay of many different pathways. Biochemical and genetic approaches have recently begun to
shed some light on the pathophysiology of these types of
ADRs. Understanding this pathophysiology is a prerequisite for development of evidence-based approaches for
better management. Two key players in the in the underlying molecular pathophysiology of immune-mediated
IDRs are the drug (or its reactive metabolites) and the
immune cells, particularly circulating lymphocytes (when
isolated from peripheral blood samples often referred to as
peripheral blood monocytes, PBMCs). In addition recent
development has led to the use of blood platelets as a
surrogate cell model for in vitro toxicity assays. According
to the ‘reactive metabolite’ hypothesis, metabolic activation of drugs to reactive metabolite(s) represents the first
step in a series of events [28]. The ‘reactive metabolite’
hypothesis postulates that IDRs develop as a result of
imbalance between metabolic activation and detoxification of drugs in the biological system leading to accumulation of one or more toxic reactive metabolites [59–61]. It
is important to understand that reactive metabolites may
not be the principle direct activator of the immune system
as parent, non-reactive drugs can activate isolated T-cells
in vitro without need for any bioactivation or processing
[32]. However, chemically reactive electrophilic metabolites seem to be the major, if perhaps not the only, products capable of supporting two important pathways in
the immune system activation process: generation of
haptenated endogenous proteins (act as antigens, signal
1) and generation of danger signals from stressed and
dying cells (signal 2, Figure 2) [16, 29]. Signal 2 can also be
provided by factors such as trauma, bacterial and viral
infections, or co-administered drugs and environmental
pollutants. The clinical manifestations of IDRs are probably
primarily mediated by the immune system although in

some cases a direct toxic effect of the reactive species
generated from the drug during metabolism may be manifested clinically [28, 59]. It has been established for several
decades that PBMCs from hypersensitive patients are
more susceptible to in vitro toxicity from the reactive
metabolite(s) of the suspected drug than are cells from
healthy individuals (controls) who have tolerated the drug
[60, 62–69]. T-cells are key mediators of any reaction that
involve the immune system and T-cells that specifically
recognize culprit drugs and their metabolites have long
been cloned from patient blood samples and characterized [70–73]. In vitro detection of these drug-specific
T-cells is considered indicative of the occurrence of
immune-mediated reactions. This is achieved by measuring T-cell proliferation in short term primary cultures as a
response to incubation with the suspected drug.
The lymphocyte transformation test (LTT) The LTT is the
most extensively studied and widely used in vitro diagnostic test for drug, food and environmental allergies. The
method was first used back in the early 1960s to evaluate
hypersensitivity reactions to phenytoin [74] and sulfa
drugs [75]. The test involved tedious visual counting of
mitotic figures until Vischer [76] adopted measuring radiolabelled thymidine incorporation into cellular DNA as a
reflection of cell division rate. Drug specific T-cell clones
can be isolated and cloned in vitro and they respond to
incubation with the culprit drug with proliferation and
expression of certain surface markers [58, 71, 77].
Technical and mechanistic aspects First, the anticoagulated blood sample is obtained from the patient
and the PBMCs are separated over density gradient
(Ficoll®). Cells are then cultured in RPMI 1640 medium
supplemented with fetal bovine serum (FBS) for 5 days
at 37°C in the presence of the concentration range of
the suspected drug (preferably in pure form). Tritiumlabelled thymidine (3H-thymidine) is then added to the
culture and cells are harvested on day 6 to count incorporated radioactivity as a measure of cell proliferation.
The increase in cell proliferation is expressed as a ratio
called the stimulation index (SI = 3H-thymidine in the
presence of the drug/3H-thymidine uptake in the absence
of the drug) [3, 18]. Other markers of T-cell stimulation
have also been used including secretion of mediators
(IL-5, IL-10) and expression of specific antigens (e.g. CD
69) [78, 79].
Probably one of the most convincing factors for the
involvement of the immune system in IDRs is the possibility to isolate drug-specific T-cell clones from blood
samples of affected patients. This represents the mechanistic basis of the LTT as a diagnostic tool for IDRs.
The sensitivity of the LTT for the diagnosis of (drug
hypersensitivity syndrome) has been estimated to be from
56% to 78% and its specificity to range from 85% to 93% [3,
80]. Factors that affect the performance of the LTT include
Br J Clin Pharmacol
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Prohapten

LTA and iPTA (Measures
accumulation of
reactive metabolite(s)

Hapten

Damaged cell
A
Danger
signals (e.g. cytokines)
D
Non-toxic
metabolite

Reactive
metabolite

APC
Modified
peptide

MHC

TCR

LTT and BAT (Measures
activated immune
cells)

Immune-mediated idiosyncratic drug reactions

Figure 2
Molecular mechanisms of immune mediated idiosyncratic drug reactions demonstrating the principle of the lymphocyte toxicity assay (LTA), the in vitro
platelet toxicity assay (iPTA), the basophil activation test (BAT) and the lymphocyte transformation test (LTT). (A = Activation); (D = detoxication); nonreactive parent drug ( ); reactive parent drug ( ); reactive metabolite ( )

(i) timing of the test with respect to the initial reaction, (ii)
the clinical picture of the reactions, (iii) the type of drug
involved and (iv) the test procedure and read-out systems
used [3, 80]. The use of LTT in the diagnosis of drug hypersensitivity reactions has recently been systematically
reviewed [3].
The lymphocyte toxicity assay (LTA) The LTA is similar to
the LTT in using isolated PBMCs, but the principle of the
assay is quite different [81]. The test is based on the observation that cells from hypersensitive patients express a
higher degree of cell death when incubated with the
culprit drug metabolite(s) than cells from healthy (drug
tolerant) controls. Clinical and practical data and theoretical explanations exist to support this hypothesis but the
validity of in vitro cell death as a marker for in vivo druginduced IDR has long been questioned [67, 82]. Our three
decade clinical and laboratory experience with the use of
the LTA in the diagnosis of drug-induced hypersensitivity
reactions have proven the test as a very useful diagnostic
tool for IDRs to many drug classes including aromatic
anticonvulsants, sulfonamides and β-lactam antibiotics
[34].
894
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Technical and mechanistic aspects The test includes
incubation of Ficoll gradient isolated PBMCs from
patients and controls with the drug in the presence of
a metabolic activation system (usually phenobarbitalinduced rat liver microsomes, RLM) or with the synthesized drug metabolite (if known and available) [81].
Following incubation with different concentrations
of the tested drug for 2 h at 37°C, cells are incubated
for recovery for 16 h and cell death is then determined using different methods (e.g. trypan blue exclusion, tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl) 2, 5
diohenyl-tetrazolium bromide (MTT)). Degrees of cell
death are expressed as percentage of the control
(cells incubated with vehicle without drug) and
compared with percentage of cell death in cells from
healthy individuals who did not experience an ADR
with the same drug (controls). A cut off value of the percentage of increase in cell death of incubated patient
cells (vs. controls) is considered as an indication of patient
susceptibility. The predictive value of the LTA remains difficult to define due to lack of a ‘gold standard’ test for
comparison and the technical complexity of the test
[3, 34].

In vitro testing for idiosyncratic adverse drug reactions

We have recently performed a population survey on a
cohort of pre-tested patients to evaluate the predictive
values of the LTA for diagnosis of IDRs to different classes
of drugs including β-lactam antibiotics, sulfonamides and
aromatic anticonvulsants [34]. In this study we included
147 patients who developed an IDR and searched for cases
of accidental or purposeful re-exposure of the patient to
the suspected drug. Among these patients we identified
26 cases of re-exposure in 22 patients. It is clear from our
evaluation that the performance of the LTA test is affected
by factors including timing of the test with respect to
the initial reaction, type of reaction and class of drugs
involved.
On the other hand, the metabolic activation system of
the LTA test lacks standardization. There are many
pharmacokinetic and pharmacodynamic factors that do
not enter the equation including lack of the absence of any
functional detoxification pathways. One important observation is that use of a synthetic reactive metabolite (e.g. as
in case of sulfonamide drugs) resulted in increased test
sensitivity and its positive predictive value [34, 62, 63].
Another factor limiting the more routine use of the LTA is
the requirement for careful isolation of PBMCs.
Recent developments Recent research in our laboratory
focused on developing and validating the use of peripheral blood platelets (PBPs) as a surrogate cell model for in
vitro toxicity testing [35, 83]. Due to their small size and low
density, PBPs are readily collectable from blood using differential centrifugation [84]. In addition to blood homeostasis, the role of platelets in inflammation, allergy and
hypersensitivity reactions has recently been recognized
[85–88]. Platelets are metabolically active and contain a
full apoptotic system, which make them a good model to
study drug toxicity in vitro. Furthermore, they do not proliferate which adds another advantage to the use of platelets as a cell model to evaluate the degree of cell death.
Cell proliferation may mask part of cell death in the PBMCs
model. Platelets from hypersensitive patients respond to
in vitro chemical insult in a similar fashion to PBMCs and
the degree of cell death is higher and easier to detect [83].
We also attributed this phenomenon to the lower capacity
of platelets for detoxication of reactive metabolites.
In a validation study of the in vitro plasma toxicity assay
(iPTA) using rigorous inclusion criteria of identified IDRs
cases to sulfa drugs, there was 85% agreement (11 out of
13) between the LTA and the iPTA results in the 13 cases
we tested. In the two clinically confirmed cases where the
two tests did not agree the LTA was negative and the iPTA
was positive. This disagreement between the LTA and the
iPTA is probably due to the higher sensitivity of the platelet test to detect patient susceptibility.
In conclusion, the iPTA offers a simplified procedure for
in vitro toxicity testing for IDRs with higher sensitivity than
the LTA. We believe that the iPTA is more suitable as a
diagnostic procedure for IDRs for wider clinical use.

Other in vitro tests for IDRs
In addition to the aforementioned specific tests, these are
other in vitro tests, which play a major role in management
of IDRs. However, most authors do not list them in their
reviews as in vitro tests for IDRs. Because management of
such a complex disease requires quick decisions based on
evidence based medicine, a global approach is the most
successful and the least costly in terms of patient wellbeing and healthcare resources. Valuable data from these
tests can guide the treatment journey to a safe port.
Tissue biopsy Microscopic examination of tissue biopsies
can be very valuable in the diagnosis of IDRs involving the
skin, the liver, lymph nodes and other tissues [89–91]. In
severe cases of skin lesions such as exanthematous
pustulosis (AGEP), DRESS and SJS/TEN skin biopsy is an
important part of disease management and may affect the
course of therapy [92]. Early detection of severe cutaneous
IDRs (CIRDs) can save lives and it is important to differentiate SJS/TEN from erythema multiforme (EM) early on
because they have different courses of therapy. Hosaka
et al. used frozen skin sections in 35 patients to differentiate TEN from EM in their early stages. From the 35 patients
nine had signs of TEN, of them six were later diagnosed
with TEN/SJS and three had EM and none of the rest developed TEN/SJS [93]. Drug-induced skin rashes have many
distinct clinical and histopathological characteristics and
features that range in severity from mild self-resolving
simple rash to life threatening bullous reactions (SJS/TEN),
and in delay time from hours to days. Each has characteristic histopathology features that can be determined in
skin biopsy samples.
Measurement of serum markers for IDRs Analysis of
peripheral blood samples of immune-mediated IDRs and
studying circulating immune cell subpopulations can help
determine the type of reaction and the underlying pathophysiology. Immediate and delayed hypersensitivity reactions have distinct circulating affector cells. Delayed
reactions are characterized by Th1 pattern with expression
of interferon γ (IFN γ), interleukin-12 (IL-12) and tumour
necrosis factor α (TNFα) and down regulation of IL-4
expression. IgE-mediated immediate reactions, on the
other hand, are characterized by Th2 pattern with production of IL-4 and downregulation of IFN γ. Fujita et al. developed a rapid immunichromatographic strip test to detect
serum granulysin for early prediction of SJS/TEN. Although
the sample size was not large enough to validate the test,
the test seems very promising as a diagnostic tool for these
severe types of reactions [94]. Soluble Fas (sFas) levels
were also found to increase significantly in sera of SJS/TEN
patients before skin detachment develops, which opens
the possibility of using this marker for early diagnosis of
SJS/TEN [95, 96]. Caproni et al. have also described that
SJS/TEN patients with wide spread skin detachment have a
high serum expression of soluble CD40L [97]. Serum
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markers for different types of IDRs is a fast growing field
which is useful for both diagnosis and understanding the
pathophysiology of the disease [98].
In vitro test for IDILI In addition to skin, the liver is the
organ most affected by IDRs, mainly because it is the main
site of drug metabolism. IDILI is a major cause of post
marketing drug withdrawal and black box warnings. IDILI
are estimated to have an incidence of 1 in 1000 to 1 in
10 000 patients with variable latency periods that ranges
from days to months and are estimated to make up 20% of
cases of severe liver injury requiring hospitalization [99]. It
has been found that paracetamol (acetaminophen) overdose and idiosyncratic reactions are the most frequent
cause of acute liver failure [100]. Prediction and prevention
of IDILI have been difficult because of the lack of a reliable
screening test and the lack of understanding of the underlying pathophysiology [101]. DILI can manifest as a main
ADR or present as part of a full drug hypersensitivity syndrome (DRESS) [25]. IDILI were responsible for 13% of
acute liver failure (ALF) in the USA between the years 1997
and 2001 [99]. DILI should be considered in any patient
with liver dysfunction. A serologic test should be used to
rule out any possibility of viral infection. Detailed history of
prescription and over the counter medications should be
taken as well as alternative and herbal products and foods
including alcohol consumption. Time of exposure should
be assessed very carefully as DILI most often occur within 6
months of drug exposure but can also occur within days or
after a year. Causality assessment can be a challenge especially in cases of multiple medications. In vitro testing for
DILI includes evaluation of liver function using liver
enzymes as biological markers. Serum concentrations of
alkaline phosphatase (ALP), alanine transaminase (ATA)

and bilirubin are indicative of the degree of liver injury.
Also hepatocellular liver injury can be differentiated from
cholestatic liver injury by measuring liver enzymes. The
latter is characterized by higher increase in alkaline phosphatase and bilirubin relative to alanine transaminase. DILI
is often characterized by the presence of anti-drug antibodies and autoantibodies but tests to measure them are
not always available [25]. Liver histology studies of biopsies or explant samples can confirm the mechanism of liver
injury, as immune cell infiltrates are indicative of immunemediated reaction.
Genetic testing Genetic testing for predisposing alleles for
IDRs has recently increased exponentially. Genetic analysis
has linked a few specific genetic polymorphisms with
certain IDRs to some drugs in specific ethnic groups (e.g.
HLA B*-1502 for carbamazepine-induced severe bullous
reactions in the Han Chinese and HLA B*-5701 and
abacavir hypersensitivity) [102]. Genetic testing has
proven to be very useful in cases such as abacavir hypersensitivity and carbamazepine SJS/TEN reactions in Han
Chinese populations. In fact, after implementing mandatory genetic testing for abacavir prescription, abacavir
hypersensitivity cases have dropped dramatically in the
last few years. Unfortunately, given the incidence of these
haplotypes and the fact that the haplotypes are not clearly
linked to mechanism, it is likely that using HLA typing to
predict risk of adverse drug effects will deny therapy to
many patients who would have tolerated the drug. These
studies have also made it clear that much more work is
required in both basic and clinical science to enable us to
predict better, manage and prevent these type of ADRs.
Further research is required to elucidate the pathophysiology of drug hypersensitivity syndrome as well as rigorous

Table 2
Pros and cons of in vitro tests available for idiosyncratic drug reactions

Detection of drug-specific
IgEs
Pros

• The test has high positive
predictive value.
• Positive results are highly
suggestive of type I
immune-mediated reaction.

Cones

• Low sensitivity and negative
predictive value.
• Traditionally the technique
involves the use of
radioactive reagents.

LTT

LTA

BAT

iPTA

• The test has been used for
a long time and has
accumulated a reasonable
amount of clinical
experience.
• Positive result demonstrates
the involvement of the
immune system in the
reaction pathophysiology.
• Expensive and requires
highly skilled personnel and
sophisticated equipment.
• Predictive value is not well
defined.

• A reasonable experience
with clinical use is available.
• In principle the test can be
used to predict potential
risk to develop a reaction
prior to exposure as it
detects phenotypic
predisposition.

• Recent adaptations of flow
cytometric methods have
increased its sensitivity.
• New techniques allow the
use of whole blood
samples.

• The test procedure is
simplified and more
reproducible.
• Smaller volume of blood
samples is needed.
• Has been shown to have a
higher sensitivity compared
with the LTA.

• Procedure is time
consuming and demands
special skills, resources and
reagents.
• Has very limited use in few
centres.

• Can detect limited types of
reactions, which involve
basophil activation.
• Has low sensitivity.
• Available only for a limited
number of drugs.

• The test has not been
validated by independent
group.

BAT, basophil activation test; iPTA, in vitro platelet toxicity assay; LTA, lymphocyte toxicity assay; LTT, lymphocyte transformation test.
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trials to determine which of the available in vitro evaluations is most suitable for the assessment of patients or
research subjects with possible DHRs.

Conclusion
Evaluation and management of IDRs require a great deal of
clinical and laboratory experience [103]. Incomplete
understanding of the underlying pathophysiology of
these complex ADRs has always been an obstacle to
develop reliable in vitro diagnostic test for this disease.
Available tests have proven to be useful tools for IDR management but they are not always available to clinicians and
are still confined to well equipped research laboratories
(Table 2). Lack of a ‘gold standard test’ for IDRs has made
accurate determination of in vitro testing predictive values
quite a challenge. Attempts should be made to simplify
and standardize in vitro testing procedure, if wider clinical
use is to be achieved. Clinicians should be aware that safe
alternative in vitro tests for severe IDRs are available in
order to avoid unnecessarily risky DPT. With a robust plan
and a multidisciplinary approach, in vitro testing can play
an important role in IDR management.
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